Coherus Oncology, Inc. (CHRS)

Coherus Oncology, Inc.'s stock price has been impacted by several events over the past six months. In Q1 2025, the company reported net revenue of $7.6 million, primarily from LOQTORZI, and completed the UDENYCA franchise divestiture. Q2 2025 saw LOQTORZI net revenue increase to $10.0 million. In Q3 2025, LOQTORZI net revenue reached $11.2 million, with a net loss from continuing operations of $(0.38) per share. Positive clinical data for CHS-114 were presented at SITC 2025. NCCN revised its treatment guidelines for NPC to designate LOQTORZI as the only treatment with Preferred status in NPC.

Coherus Oncology, Inc.'s products have been impacted by seasonal inventory drawdown by wholesalers, which affected LOQTORZI revenue in Q1 2025, despite strong underlying patient demand growth. This suggests some level of seasonality in the purchasing patterns of wholesalers for its products.

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on innovative immuno-oncology therapies. The company has shifted its focus from biosimilars to innovative oncology, completing the divestiture of its UDENYCA franchise in April 2025. Key products include LOQTORZI, an FDA-approved PD-1 inhibitor for nasopharyngeal carcinoma, CHS-114, an anti-CCR8 antibody in Phase 1b studies, and Casdozokitug, an IL-27 antagonistic antibody in Phase 1/2 and Phase 2 studies.

Coherus Oncology, Inc. is headquartered in Redwood City, California. The company has expanded its commercial footprint in the U.S. and is exploring opportunities in Europe and Asia. The company primarily generates revenue from the United States.

Coherus Oncology, Inc.'s brand reputation has been positively influenced by its strategic pivot to innovative oncology and the performance of its key products and pipeline. The FDA approval of LOQTORZI and its subsequent designation as a preferred treatment by NCCN have bolstered the company's standing in the oncology space. Promising clinical data for pipeline candidates like CHS-114 and Casdozokitug, particularly in challenging cancer indications, further enhance its scientific credibility and future prospects. The divestiture of its biosimilar business is framed as a move to streamline operations and focus on high-value oncology assets.

Coherus Oncology, Inc. has a mixed ownership structure, with approximately 26.50% of the company's stock owned by Institutional Investors, 1.08% by Insiders, and 9.16% by Public Companies and Individual Investors. Major institutional owners include BlackRock, Inc., The Vanguard Group, Inc., Tang Capital Management LLC, Kohlberg Kravis Roberts & Co. L.P., Geode Capital Management, LLC and State Street Global Advisors, Inc.